IFNA1 and melanoma: Incorporating baseline IFN signatures, spatially mapped immune-IFN modules, and dynamic IFN induction into predictive models may therefore deepen our ability to stratify patients, tailor immunotherapy combinations, and monitor early immune activation in melanoma.